Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

The proposal would see the HHS set price targets other countries pay for certain medicines, kicking off a round of ...

The biotech has quickly turned a cell therapy approval into one of the more lucrative recent sales for a priority review ...

Improvements in our understanding of the human genome, technological tools like artificial intelligence, and global ...

The big pharma will spend up to $250 million over the next eight years of the collaboration. Elsewhere, CRISPR Therapeutics unveiled new data and Vivo Capital raised funds.

Some providers may need to reduce services, lay off staff or close their doors if Congress enacts major cuts to the ...

Vor Bio, Korro Bio, Insitro and Rallybio revealed plans to lay off chunks of their respective workforces in the latest job ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

The company added to a recent flurry of pledges by pharmaceutical companies, promising $11 billion in new capital and ...

The startup’s first prospect is a heart medicine that works differently than the hypertrophic cardiomyopathy drugs developed ...

To hear Vinay Prasad tell it, U.S. healthcare is too ready to intervene unnecessarily, use prescription drugs without sufficient evidence of their benefit and put patients at risk of side effects or ...